Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
08:18am, Wednesday, 03'rd Jun 2026
WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announc
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 02'nd Jun 2026
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announc
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and
My Top 3 Biotech Stocks for May 2026
11:15am, Wednesday, 20'th May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty
06:42am, Wednesday, 20'th May 2026
NRx Pharmaceuticals (NRXP) is downgraded from 'Buy' to 'Sell' following failures in ZYESAMI and NRX-101 clinical trials. Company's KETAFREE and NRX-100 programs offer potential, but face significant r
NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
10:01am, Monday, 18'th May 2026
NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
NRx Pharmaceuticals Q1 Earnings Call Highlights
09:05am, Monday, 18'th May 2026
NRx Pharmaceuticals NASDAQ: NRXP said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its prese
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Monday, 18'th May 2026
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
06:56pm, Friday, 15'th May 2026
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.34 per share a year ago.
NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
06:32am, Friday, 15'th May 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
07:00am, Thursday, 14'th May 2026
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inf
Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospita
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
07:00am, Tuesday, 05'th May 2026
Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer. NRx has completed confirmatory GMP audits of ma
